A Harvard study shows that semaglutide is related to rare vision loss. Novo Nordisk (NVO.US) leads the weight loss drug concept stocks in decline.
A Harvard study shows that the weight loss drugs Ozempic and Wegovy from Novo Nordisk A/S may be associated with rare vision loss.
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $65
Cantor Fitzgerald analyst Prakhar Agrawal maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $65.According to TipRanks data, the analyst has a success rat
Analysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and UnitedHealth (UNH)
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Jefferies analyst Roger Song maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $79.According to TipRanks data, the analyst has a success rate of 30.2% an
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100
BMO Capital analyst Evan Seigerman maintains $Structure Therapeutics(GPCR.US)$ with a buy rating, and maintains the target price at $100.According to TipRanks data, the analyst has a success rate of 4
Pfizer's CEO announced the development of three new weight loss drugs, one of which is not a GLP-1 medication.
Pfizer's (PFE.US) CEO, Albert Bourla, said that the pharmaceutical company is testing three new weight loss drugs.
Goldman Sachs and Cantor Fitzgerald have a tacit agreement that the monopoly of "Norris" in the weight loss drug market is difficult to change.
Two top Wall Street analysts have reached a consensus, emphasizing that global weight loss drug market leaders "Novo" may continue to dominate the highly profitable weight loss drug market.
Obesity-Drug Developers Look at What's Next for a $100 Billion Market -- Barrons.com
Weight-loss drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, have launched a market that analysts expect will grow to $100 billion in 10 years. Drug developers from those firms and others are looking at ways to improve upon those big-selling drugs.
Structure Therapeutics Price Target Maintained With a $65.00/Share by Cantor Fitzgerald
Structure Therapeutics Price Target Maintained With a $65.00/Share by Cantor Fitzgerald
Cantor Fitzgerald Reiterates Overweight on Structure Therapeutics, Maintains $65 Price Target
Cantor Fitzgerald analyst Prakhar Agrawal reiterates Structure Therapeutics (NASDAQ:GPCR) with a Overweight and maintains $65 price target.
Could Structure Therapeutics Become the Next Novo Nordisk?
USA faces the most severe drug shortage in a decade, with low stock price drugs and weight loss drugs becoming "disaster zones".
Last year, the USA experienced the most serious drug shortage crisis in a decade.
Real-life version of 'Dying to Survive'? Jpmorgan spent $500 million to seize the weight-loss track.
JPMorgan's asset management department has raised over $500 million for a biotechnology venture capital fund that will bet on the hottest area in medical care: weight loss drugs.
JPMorgan to Wager on Weight-Loss Craze With $500 Million Fund
JPMorgan Chase & Co.’s asset-management arm raised more than $500 million for a biotech venture-capital fund that will bet on the hottest corner of health care: weight-loss drugs
GLP-1 Obesity Drug Coverage Dropped by Blue Cross Michigan: Report
Structure Therapeutics (GPCR) Rallying on Obesity Drug Data
Structure Therapeutics Stock Could Rocket 87% Higher, According to 1 Wall Street Analyst. Is It Time to Buy?
Structure Therapeutics' Stock Is Soaring on the Promise of Its Wegovy Competitor, but Is It a Buy?
Press Release: Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares
Structure Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional American Depositary Shares SAN FRANCISCO, June 07, 2024 (GLOBE
Structure Therapeutics Is Maintained at Outperform by BMO Capital
Structure Therapeutics Is Maintained at Outperform by BMO Capital